Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2021

27.06.2020 | Thoracic Oncology

Prognostic Implication of Postoperative Weight Loss After Esophagectomy for Esophageal Squamous Cell Cancer

verfasst von: Yuto Kubo, MD, Hiroshi Miyata, MD, Keijiro Sugimura, MD, Naoki Shinno, MD, Kei Asukai, MD, Shinitiro Hasegawa, MD, Yoshitomo Yanagimoto, MD, Daisaku Yamada, MD, Kazuyoshi Yamamoto, MD, Junichi Nishimura, MD, Hiroshi Wada, MD, Hidenori Takahashi, MD, Masayoshi Yasui, MD, Takeshi Omori, MD, Masayuki Ohue, MD, Masahiko Yano, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Preoperative weight loss in esophageal cancer is reported to be associated with a poor prognosis. However, the impact of postoperative weight loss on the prognosis of patients with esophageal cancer remains unclear.

Methods

This study included 186 patients with esophageal squamous cell carcinoma who underwent surgery between January 2012 and January 2015. The relationship between weight loss 6 months after esophagectomy as well as the clinical factors and prognosis of patients was investigated.

Results

The mean weight loss rate for all the patients was 9.3% at 3 months, 10.8% at 6 months, 11.1% at 12 months, and 11.4% at 24 months after surgery. The patients with severe weight loss 6 months after surgery (≥ 12%) exhibited lower serum albumin levels and a lower prognostic nutrition index 6 months after esophagectomy than the patients with moderate weight loss (< 12%; p = 0.011 and 0.009, respectively). Although overall survival did not differ significantly between the two groups, for all the patients, severe weight loss was significantly associated with shortened overall survival for the cStages 3 and 4 patients (3-year overall survival rate, 76.6% in the moderate group vs 54.5% in the severe group; p = 0.042). The multivariate analyses identified only severe weight loss as an independent factor associated with worse overall survival for the cStages 3 and 4 patients (p = 0.034).

Conclusion

This study showed that postoperative weight loss negatively affected the prognosis for patients with advanced esophageal cancer, indicating the necessity of administering nutritional interventions to these patients to prevent postoperative weight loss.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bollschweiler E, Plum P, Monig SP, Holscher AH. Current and future treatment options for esophageal cancer in the elderly. Expert Opin Pharmacother. 2017;18:1001–10.CrossRef Bollschweiler E, Plum P, Monig SP, Holscher AH. Current and future treatment options for esophageal cancer in the elderly. Expert Opin Pharmacother. 2017;18:1001–10.CrossRef
2.
Zurück zum Zitat Gockel I, Niebisch S, Ahlbrand C, et al. Risk and complication management in esophageal cancer surgery: a review of the literature. Thorac Cardiovasc Surg. 2016;64:596–605.CrossRef Gockel I, Niebisch S, Ahlbrand C, et al. Risk and complication management in esophageal cancer surgery: a review of the literature. Thorac Cardiovasc Surg. 2016;64:596–605.CrossRef
3.
Zurück zum Zitat Martin L, Lagergren J, Lindblad M, Rouvelas I, Lagergren P. Malnutrition after oesophageal cancer surgery in Sweden. Br J Surg. 2007;94:1496–500.CrossRef Martin L, Lagergren J, Lindblad M, Rouvelas I, Lagergren P. Malnutrition after oesophageal cancer surgery in Sweden. Br J Surg. 2007;94:1496–500.CrossRef
4.
Zurück zum Zitat Lagergren J, Lagergren P, Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63:232–8.CrossRef Lagergren J, Lagergren P, Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63:232–8.CrossRef
5.
Zurück zum Zitat Riccardi D, Allen K, Nutritional management of patients with esophageal and esophagogastric junction cancer. Cancer Control. 1999;6:64–72.CrossRef Riccardi D, Allen K, Nutritional management of patients with esophageal and esophagogastric junction cancer. Cancer Control. 1999;6:64–72.CrossRef
6.
Zurück zum Zitat Anandavadivelan P, Wikman A, Johar A, Lagergren P. Impact of weight loss and eating difficulties on health-related quality of life up to 10 years after oesophagectomy for cancer. Br J Surg. 2018;105:410–8.CrossRef Anandavadivelan P, Wikman A, Johar A, Lagergren P. Impact of weight loss and eating difficulties on health-related quality of life up to 10 years after oesophagectomy for cancer. Br J Surg. 2018;105:410–8.CrossRef
7.
Zurück zum Zitat Elliott JA, Docherty NG, Eckhardt HG, et al. Weight loss, satiety, and the postprandial gut hormone response after esophagectomy: a prospective study. Ann Surg. 2017;266:82–90.CrossRef Elliott JA, Docherty NG, Eckhardt HG, et al. Weight loss, satiety, and the postprandial gut hormone response after esophagectomy: a prospective study. Ann Surg. 2017;266:82–90.CrossRef
8.
Zurück zum Zitat Baker M, Halliday V, Williams RN, Bowrey DJ. A systematic review of the nutritional consequences of esophagectomy. Clin Nutr. 2016;35:987–94.CrossRef Baker M, Halliday V, Williams RN, Bowrey DJ. A systematic review of the nutritional consequences of esophagectomy. Clin Nutr. 2016;35:987–94.CrossRef
9.
Zurück zum Zitat Ludwig DJ, Thirlby RC, Low DE. A prospective evaluation of dietary status and symptoms after near-total esophagectomy without gastric emptying procedure. Am J Surg. 2001;181:454–8.CrossRef Ludwig DJ, Thirlby RC, Low DE. A prospective evaluation of dietary status and symptoms after near-total esophagectomy without gastric emptying procedure. Am J Surg. 2001;181:454–8.CrossRef
10.
Zurück zum Zitat Haverkort EB, Binnekade JM, Busch OR, et al. Presence and persistence of nutrition-related symptoms during the first year following esophagectomy with gastric tube reconstruction in clinically disease-free patients. World J Surg. 2010;34:2844–52.CrossRef Haverkort EB, Binnekade JM, Busch OR, et al. Presence and persistence of nutrition-related symptoms during the first year following esophagectomy with gastric tube reconstruction in clinically disease-free patients. World J Surg. 2010;34:2844–52.CrossRef
11.
Zurück zum Zitat D’Journo XB, Ouattara M, Loundou A, et al.. Prognostic impact of weight loss in 1-year survivors after transthoracic esophagectomy for cancer. Dis Esophagus. 2012;25:527–34.CrossRef D’Journo XB, Ouattara M, Loundou A, et al.. Prognostic impact of weight loss in 1-year survivors after transthoracic esophagectomy for cancer. Dis Esophagus. 2012;25:527–34.CrossRef
12.
Zurück zum Zitat Martin L, Lagergren P. Risk factors for weight loss among patients surviving 5 years after esophageal cancer surgery. Ann Surg Oncol. 2015;22:610–6.CrossRef Martin L, Lagergren P. Risk factors for weight loss among patients surviving 5 years after esophageal cancer surgery. Ann Surg Oncol. 2015;22:610–6.CrossRef
13.
Zurück zum Zitat Liu J, Xie X, Zhou C, et al. Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma? Eur J Cardiothorac Surg. 2012;41:e7–11.CrossRef Liu J, Xie X, Zhou C, et al. Which factors are associated with actual 5-year survival of oesophageal squamous cell carcinoma? Eur J Cardiothorac Surg. 2012;41:e7–11.CrossRef
14.
Zurück zum Zitat Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. 8th ed. Wiley, New York, 2017. Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. 8th ed. Wiley, New York, 2017.
15.
Zurück zum Zitat Sugimura K, Miyata, H, Shinno N, et al. Prognostic factors for esophageal squamous cell carcinoma treated with neoadjuvant docetaxel/cisplatin/5-fluorouracil followed by surgery. Oncology. 2019;97:1–8.CrossRef Sugimura K, Miyata, H, Shinno N, et al. Prognostic factors for esophageal squamous cell carcinoma treated with neoadjuvant docetaxel/cisplatin/5-fluorouracil followed by surgery. Oncology. 2019;97:1–8.CrossRef
16.
Zurück zum Zitat Kubo Y, Miyata H, Sugimura K, et al. Prophylactic effect of premedication with intravenous magnesium on renal dysfunction in preoperative cisplatin-based chemotherapy for esophageal cancer. Oncology. 2019;97:319–26.CrossRef Kubo Y, Miyata H, Sugimura K, et al. Prophylactic effect of premedication with intravenous magnesium on renal dysfunction in preoperative cisplatin-based chemotherapy for esophageal cancer. Oncology. 2019;97:319–26.CrossRef
17.
Zurück zum Zitat Miyata H, Sugimura K, Yamasaki M, et al. Clinical impact of the location of lymph node metastases after neoadjuvant chemotherapy for middle and lower thoracic esophageal cancer. Ann Surg Oncol. 2019;26:200–8.CrossRef Miyata H, Sugimura K, Yamasaki M, et al. Clinical impact of the location of lymph node metastases after neoadjuvant chemotherapy for middle and lower thoracic esophageal cancer. Ann Surg Oncol. 2019;26:200–8.CrossRef
18.
Zurück zum Zitat Miyata H, Sugimura K, Yamasaki M, et al. Clinical implications of conversion surgery after induction therapy for T4b thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2019;26:4737–43.CrossRef Miyata H, Sugimura K, Yamasaki M, et al. Clinical implications of conversion surgery after induction therapy for T4b thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2019;26:4737–43.CrossRef
19.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRef Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRef
20.
Zurück zum Zitat Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85:1001–5.PubMed Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85:1001–5.PubMed
21.
Zurück zum Zitat Kudou K, Saeki H, Nakashima Y, et al. C-reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer. J Gastroenterol Hepatol. 2019;34:355–63.CrossRef Kudou K, Saeki H, Nakashima Y, et al. C-reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer. J Gastroenterol Hepatol. 2019;34:355–63.CrossRef
22.
Zurück zum Zitat Lagarde SM, de Boer JD, ten Kate FJ, et al. Postoperative complications after esophagectomy for adenocarcinoma of the esophagus are related to timing of death due to recurrence. Ann Surg. 2008;247:71–6.CrossRef Lagarde SM, de Boer JD, ten Kate FJ, et al. Postoperative complications after esophagectomy for adenocarcinoma of the esophagus are related to timing of death due to recurrence. Ann Surg. 2008;247:71–6.CrossRef
23.
Zurück zum Zitat Takahashi K, Watanabe M, Kozuki R, et al. Prognostic significance of skeletal muscle loss during early postoperative period in elderly patients with esophageal cancer. Ann Surg Oncol. 2019;26:3727–35.CrossRef Takahashi K, Watanabe M, Kozuki R, et al. Prognostic significance of skeletal muscle loss during early postoperative period in elderly patients with esophageal cancer. Ann Surg Oncol. 2019;26:3727–35.CrossRef
24.
Zurück zum Zitat Okada G, Momoki C, Habu D, et al. Effect of postoperative oral intake on prognosis for esophageal cancer. Nutrients. 2019;11:E1338.CrossRef Okada G, Momoki C, Habu D, et al. Effect of postoperative oral intake on prognosis for esophageal cancer. Nutrients. 2019;11:E1338.CrossRef
25.
Zurück zum Zitat Glickman JN, Torres C, Wang HH, et al. The prognostic significance of lymph node micrometastasis in patients with esophageal carcinoma. Cancer. 1999;85:769–78.CrossRef Glickman JN, Torres C, Wang HH, et al. The prognostic significance of lymph node micrometastasis in patients with esophageal carcinoma. Cancer. 1999;85:769–78.CrossRef
26.
Zurück zum Zitat Sato F, Shimada Y, Li Z, et al. Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma. Br J Surg. 2001;88:426–32.CrossRef Sato F, Shimada Y, Li Z, et al. Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma. Br J Surg. 2001;88:426–32.CrossRef
27.
Zurück zum Zitat Marti A, Marcos A, Martinez JA. Obesity and immune function relationships. Obes Rev. 2001;2:131–40.CrossRef Marti A, Marcos A, Martinez JA. Obesity and immune function relationships. Obes Rev. 2001;2:131–40.CrossRef
28.
Zurück zum Zitat Ouattara M, D’Journo XB, Loundou A, et al. Body mass index kinetics and risk factors of malnutrition one year after radical oesophagectomy for cancer. Eur J Cardiothorac Surg. 2012;41:1088–93.CrossRef Ouattara M, D’Journo XB, Loundou A, et al. Body mass index kinetics and risk factors of malnutrition one year after radical oesophagectomy for cancer. Eur J Cardiothorac Surg. 2012;41:1088–93.CrossRef
29.
Zurück zum Zitat Kitagawa H, Namikawa T, Munekage M, et al. Analysis of factors associated with weight loss after esophagectomy for esophageal cancer. Anticancer Res. 2016;36:5409–12.CrossRef Kitagawa H, Namikawa T, Munekage M, et al. Analysis of factors associated with weight loss after esophagectomy for esophageal cancer. Anticancer Res. 2016;36:5409–12.CrossRef
30.
Zurück zum Zitat Schandl A, Kauppila JH, Anandavadivelan P, Johar A, Lagergren P. Predicting the risk of weight loss after esophageal cancer surgery. Ann Surg Oncol. 2019;26:2385–91.CrossRef Schandl A, Kauppila JH, Anandavadivelan P, Johar A, Lagergren P. Predicting the risk of weight loss after esophageal cancer surgery. Ann Surg Oncol. 2019;26:2385–91.CrossRef
31.
Zurück zum Zitat Sugiyama K, Narita Y, Mitani S, et al. Baseline sarcopenia and skeletal muscle loss during chemotherapy affect survival outcomes in metastatic gastric cancer. Anticancer Res. 2018;38:5859–66.CrossRef Sugiyama K, Narita Y, Mitani S, et al. Baseline sarcopenia and skeletal muscle loss during chemotherapy affect survival outcomes in metastatic gastric cancer. Anticancer Res. 2018;38:5859–66.CrossRef
32.
Zurück zum Zitat Nagata M, Ito H, Yoshida T, et al. Risk factors for progressive sarcopenia 6 months after complete resection of lung cancer: what can thoracic surgeons do against sarcopenia? J Thorac Dis. 2020;12:307–318.CrossRef Nagata M, Ito H, Yoshida T, et al. Risk factors for progressive sarcopenia 6 months after complete resection of lung cancer: what can thoracic surgeons do against sarcopenia? J Thorac Dis. 2020;12:307–318.CrossRef
Metadaten
Titel
Prognostic Implication of Postoperative Weight Loss After Esophagectomy for Esophageal Squamous Cell Cancer
verfasst von
Yuto Kubo, MD
Hiroshi Miyata, MD
Keijiro Sugimura, MD
Naoki Shinno, MD
Kei Asukai, MD
Shinitiro Hasegawa, MD
Yoshitomo Yanagimoto, MD
Daisaku Yamada, MD
Kazuyoshi Yamamoto, MD
Junichi Nishimura, MD
Hiroshi Wada, MD
Hidenori Takahashi, MD
Masayoshi Yasui, MD
Takeshi Omori, MD
Masayuki Ohue, MD
Masahiko Yano, MD
Publikationsdatum
27.06.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08762-6

Weitere Artikel der Ausgabe 1/2021

Annals of Surgical Oncology 1/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.